US · Healthcare · Biotechnology
EPS came in at -1.55 against a street estimate of 1.00 — a miss of 255.0%.
Analysts rate Viking Therapeutics Inc a strong buy (19 buy, 2 hold, 0 sell out of 21) with an average price target of $95.05.
CONFIDENT Viking advanced four Phase III VK2735 studies, reported strong maintenance signals, began oral Phase III Sunrise, and ended Q3 with $960 million in cash and investments. Q3 FY26 Cash, cash equivalents and short-term investments were $960 million at September 30, 2026, supported by approximately $550 million of net financing proceeds. Analysts focused on cross-trial comparability, oral dose selection and titration, commercial readiness, maintenance-label potential, and pipeline expansion. Management emphasized caution on comparisons, practical dose and economics considerations, and continued infrastructure building. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 4.98% |
| BlackRock Inc | 4.87% |
| State Street Corp | 4.41% |
| Vanguard Capital Management, LLC | 3.97% |
| Vanguard Portfolio Management, LLC | 3.53% |
| Two Sigma Investments LLC | 3.10% |
| Morgan Stanley - Brokerage Accounts | 2.74% |
| Ameriprise Financial Inc | 1.70% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. It h | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $—; Viking remains a clinical-stage company with no product sales. • Q3 2026 net loss was $183.2 million, or | 2026-10-28 |
| Material agreement · Q3 2026 HEADLINE NUMBERS • Viking Therapeutics raised approximately $547.8 million in net proceeds through simultaneous stock and convertible-debt offerings, | 2026-09-28 |
| Company announcement · Q3 2026 VIKING THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company announced top-line results from a maintenance study of VK2735 on September 22, 20 | 2026-09-22 |
| Quarterly report · Q2 2026 VIKING THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and short-term investments combined: $501.7 million as of June 30, 2026 ( | 2026-07-29 |
| Results announced · Q3 2026 VIKING THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $502 million in cash, cash equivalents, and short-term investments a | 2026-07-29 |
| Shareholder vote results · Q2 2026 VIKING THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 19, 2026 • 115,893,943 total shares outstanding as of March 20, 2 | 2026-05-26 |
| Quarterly report · Q1 2026 VIKING THERAPEUTICS, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash and short-term investments combined: $602.964 million (March 31, 2026), d | 2026-04-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 obesity trial enrollment complete; oral formulation advancing to Phase 3 Viking Therapeutics, a clinical-stage biotech company, announced strong progress on its obesity drug pipeline. The company's lead candidate VK2735—a dual GLP-1/GIP receptor agonist—completed | 2026-02-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Viking Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.